FDA Approves Neurolief’s At-Home Neuromod for Depression

The FDA’s New Tzield Approval Fundamentally Alters Stage 3 Pediatric Type 1 Diabetes Management

FDA approval of Tzield marks a breakthrough in Type 1 diabetes care, preserving remaining insulin-producing cells and shifting treatment from replacement to disease modification.

Re-evaluating N- Acetylcysteine as a Time-Buying Neuroprotectant in Acute Stroke Care

N-acetylcysteine (NAC) shows promise as a neuroprotective adjunct in acute ischemic stroke, potentially preserving brain tissue, enhancing reperfusion outcomes, and improving recovery during treatment delays.

Metabolomic Signature May Predict Type 2 Diabetes Risk

A novel 44-metabolite signature improves prediction of future type 2 diabetes risk, enabling earlier identification of high-risk individuals and supporting personalized prevention strategies.

Many Children with Uncontrolled Asthma Lack Access to Specialty Care

Digital health and telemedicine are transforming healthcare delivery through virtual care, remote monitoring, and enhanced patient engagement, improving access, efficiency, outcomes, and care coordination.

FDA Report on Forever Chemicals: Implications for Cosmetics

FDA scrutiny of PFAS “forever chemicals” in cosmetics may drive stricter regulations, reformulated products, greater labeling transparency, and increased consumer demand for safer beauty options.